Scholarlink

<p>In the present study, attention was given to <i>Enterococcus faecalis</i> and <i>Klebsiella pneumoniae</i> commonly causing healthcare-associated infections highly recalcitrant to antimicrobial therapy, also for their ability to form biofilms. These pathogens are often associated with a high risk of urinary tract infections due to biofilm-related complications in indwelling devices, commonly used in urological surgery. Currently, research is focusing on the development of new therapeutic strategies aimed at targeting bacterial virulence factors, such as biofilm, to reduce the increasing development of multidrug-resistant pathogens. In the present research, the activity of two antibiofilm proteins deriving from Antarctic marine bacteria, <i>Psy</i>Omp38 and Cold-Azurin, was evaluated on a collection of clinical <i>E. faecalis</i> and <i>K. pneumoniae</i> strains. In particular, the antibiofilm capabilities of <i>Psy</i>Omp38 and Cold-Azurin were tested against clinical bacterial strains characterized by different antimicrobial resistant profiles during distinctive phasis of biofilm development: initial attachment to the surface, pre-adhesion period and mature biofilm. This study provides interesting insights into the mechanism of action of the two proteins at different stages of the biofilm. Both proteins are able to impair, with different capabilities, biofilm formation of almost all bacterial tested strains. While Cold-Azurin disrupts mature biofilm only in a limited number of bacterial strains, <i>Psy</i>Omp38 shows disrupting activity against all <i>Klebsiella</i> strains and almost all <i>E. faecalis</i> strains. These findings suggest that Antarctic-derived proteins, particularly PsyOmp38, may represent promising candidates for the development of novel antibiofilm strategies against multidrug-resistant ESKAPE pathogens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

New Proteins from Cold: Antibiofilm Activity of Cold-Azurin and PsyOmp38 Against Enterococcus faecalis and Klebsiella pneumoniae

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月6日

查看全文
  • Martina Fionda,
  • Marika Trecca,
  • Diana Olimpo,
  • Caterina D’Angelo,
  • Maria Luisa Tutino,
  • Orlando Donfrancesco,
  • Michela Relucenti,
  • Laura Selan,
  • Marco Artini,
  • Ermenegilda Parrilli,
  • Rosanna Papa

摘要

In the present study, attention was given to Enterococcus faecalis and Klebsiella pneumoniae commonly causing healthcare-associated infections highly recalcitrant to antimicrobial therapy, also for their ability to form biofilms. These pathogens are often associated with a high risk of urinary tract infections due to biofilm-related complications in indwelling devices, commonly used in urological surgery. Currently, research is focusing on the development of new therapeutic strategies aimed at targeting bacterial virulence factors, such as biofilm, to reduce the increasing development of multidrug-resistant pathogens. In the present research, the activity of two antibiofilm proteins deriving from Antarctic marine bacteria, PsyOmp38 and Cold-Azurin, was evaluated on a collection of clinical E. faecalis and K. pneumoniae strains. In particular, the antibiofilm capabilities of PsyOmp38 and Cold-Azurin were tested against clinical bacterial strains characterized by different antimicrobial resistant profiles during distinctive phasis of biofilm development: initial attachment to the surface, pre-adhesion period and mature biofilm. This study provides interesting insights into the mechanism of action of the two proteins at different stages of the biofilm. Both proteins are able to impair, with different capabilities, biofilm formation of almost all bacterial tested strains. While Cold-Azurin disrupts mature biofilm only in a limited number of bacterial strains, PsyOmp38 shows disrupting activity against all Klebsiella strains and almost all E. faecalis strains. These findings suggest that Antarctic-derived proteins, particularly PsyOmp38, may represent promising candidates for the development of novel antibiofilm strategies against multidrug-resistant ESKAPE pathogens.